-
1
-
-
80155150460
-
Quantifying factors for the success of stratified medicine
-
Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011; 10:817-833.
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 817-833
-
-
Trusheim, M.R.1
Burgess, B.2
Hu, S.X.3
Long, T.4
Averbuch, S.D.5
Flynn, A.A.6
-
2
-
-
28444467388
-
Pharmacogenomics and drug development
-
Guo Y, Shafer S, Weller P, Usuka J, Peltz G. Pharmacogenomics and drug development. Pharmacogenomics 2005; 6:857-864.
-
(2005)
Pharmacogenomics
, vol.6
, pp. 857-864
-
-
Guo, Y.1
Shafer, S.2
Weller, P.3
Usuka, J.4
Peltz, G.5
-
3
-
-
84862777541
-
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
-
Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-617.
-
(2012)
Nature
, vol.483
, pp. 613-617
-
-
Chen, Z.1
Cheng, K.2
Walton, Z.3
Wang, Y.4
Ebi, H.5
Shimamura, T.6
-
6
-
-
70350243185
-
A holistic strategy for characterizing the safety of metabolites through drug discovery and development
-
Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 2009; 22:1653-1662.
-
(2009)
Chem Res Toxicol
, vol.22
, pp. 1653-1662
-
-
Walker, D.1
Brady, J.2
Dalvie, D.3
Davis, J.4
Dowty, M.5
Duncan, J.N.6
-
7
-
-
62249142787
-
Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development
-
Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 2009; 22:280-293.
-
(2009)
Chem Res Toxicol
, vol.22
, pp. 280-293
-
-
Leclercq, L.1
Cuyckens, F.2
Mannens, G.S.3
De Vries, R.4
Timmerman, P.5
Evans, D.C.6
-
8
-
-
79951576827
-
The reconstituted 'humanized liver' in TK-NOG mice is mature and functional
-
Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, et al. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 2011; 405:405-410.
-
(2011)
Biochem Biophys Res Commun
, vol.405
, pp. 405-410
-
-
Hasegawa, M.1
Kawai, K.2
Mitsui, T.3
Taniguchi, K.4
Monnai, M.5
Wakui, M.6
-
9
-
-
70449090414
-
In vivo modeling of human liver for pharmacological study using humanized mouse
-
Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2009; 5:1435-1446.
-
(2009)
Expert Opin Drug Metab Toxicol
, vol.5
, pp. 1435-1446
-
-
Yoshizato, K.1
Tateno, C.2
-
10
-
-
77949750816
-
New Horizons for studying human hepatotropic infections
-
De Jong YP, Rice CM, Ploss A. New Horizons for studying human hepatotropic infections. J Clin Invest 2010; 120:650-653.
-
(2010)
J Clin Invest
, vol.120
, pp. 650-653
-
-
De Jong, Y.P.1
Rice, C.M.2
Ploss, A.3
-
11
-
-
18344410760
-
NOD/SCID/gamma (c)(null) mouse: An excellent recipient mouse model for engraftment of human cells
-
Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma (c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100:3175-3182.
-
(2002)
Blood
, vol.100
, pp. 3175-3182
-
-
Ito, M.1
Hiramatsu, H.2
Kobayashi, K.3
Suzue, K.4
Kawahata, M.5
Hioki, K.6
-
12
-
-
84872743384
-
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction
-
press
-
Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, et al. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 2012 (in press).
-
(2012)
J Pharmacol Exp Ther
-
-
Nishimura, T.1
Hu, Y.2
Wu, M.3
Pham, E.4
Suemizu, H.5
Elazar, M.6
-
13
-
-
50049083535
-
Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma
-
Sparidans RW, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872:77-82.
-
(2008)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.872
, pp. 77-82
-
-
Sparidans, R.W.1
Lagas, J.S.2
Schinkel, A.H.3
Schellens, J.H.4
Beijnen, J.H.5
-
14
-
-
0036394942
-
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
-
Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-958.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 913-958
-
-
Desta, Z.1
Zhao, X.2
Shin, J.G.3
Flockhart, D.A.4
-
15
-
-
79960613122
-
Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
-
Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328-332.
-
(2011)
Clin Pharmacol Ther
, vol.90
, pp. 328-332
-
-
Scott, S.A.1
Sangkuhl, K.2
Gardner, E.E.3
Stein, C.M.4
Hulot, J.S.5
Johnson, J.A.6
-
16
-
-
0034752109
-
CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase
-
Zhou HH. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 2001; 313:203-208.
-
(2001)
Clin Chim Acta
, vol.313
, pp. 203-208
-
-
Zhou, H.H.1
-
17
-
-
0036263813
-
Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data
-
Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 251-263
-
-
Lee, C.R.1
Goldstein, J.A.2
Pieper, J.A.3
-
18
-
-
0141791128
-
Cytochrome P450 enzyme polymorphisms and adverse drug reactions
-
Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192:23-32.
-
(2003)
Toxicology
, vol.192
, pp. 23-32
-
-
Pirmohamed, M.1
Park, B.K.2
-
19
-
-
0042512396
-
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
-
Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59:221-225.
-
(2003)
Eur J Clin Pharmacol
, vol.59
, pp. 221-225
-
-
Dorado, P.1
Berecz, R.2
Norberto, M.J.3
Yasar, U.4
Dahl, M.L.5
Llerena, A.6
-
21
-
-
77950363916
-
Cytochrome P450 2C9-CYP2C9
-
Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010; 20:277-281.
-
(2010)
Pharmacogenet Genomics
, vol.20
, pp. 277-281
-
-
Van Booven, D.1
Marsh, S.2
McLeod, H.3
Carrillo, M.W.4
Sangkuhl, K.5
Klein, T.E.6
Altman, R.B.7
-
22
-
-
0034074957
-
Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9&z.ast;3 allele
-
Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9&z.ast;3 allele. Eur J Clin Pharmacol 2000; 56:65-68.
-
(2000)
Eur J Clin Pharmacol
, vol.56
, pp. 65-68
-
-
Shimamoto, J.1
Ieiri, I.2
Urae, A.3
Kimura, M.4
Irie, S.5
Kubota, T.6
-
23
-
-
0346784817
-
Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: No relationship to the CYP2C9 genetic polymorphism in humans
-
Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55:51-61.
-
(2003)
Br J Clin Pharmacol
, vol.55
, pp. 51-61
-
-
Kirchheiner, J.1
Meineke, I.2
Steinbach, N.3
Meisel, C.4
Roots, I.5
Brockmoller, J.6
-
24
-
-
62249093071
-
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites
-
Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 2009; 22:357-368.
-
(2009)
Chem Res Toxicol
, vol.22
, pp. 357-368
-
-
Dalvie, D.1
Obach, R.S.2
Kang, P.3
Prakash, C.4
Loi, C.M.5
Hurst, S.6
-
25
-
-
84856007232
-
The promise of induced pluripotent stem cells in research and therapy
-
Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481:295-305.
-
(2012)
Nature
, vol.481
, pp. 295-305
-
-
Robinton, D.A.1
Daley, G.Q.2
-
26
-
-
79955904906
-
In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins
-
Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011; 3:82ra39.
-
(2011)
Sci Transl Med
, vol.3
-
-
Liu, H.1
Kim, Y.2
Sharkis, S.3
Marchionni, L.4
Jang, Y.Y.5
|